Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialNicholas D. James, Mahesh Parmar, George N. Thalmann et al.|The Lancet|2015Cited by 2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone TherapyNicholas D. James, Matthew R. Sydes, Johann S. de Bono et al.|New England Journal of Medicine|2017Cited by 1.8k
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.Nicholas D. James, Laura Murphy, Noel W. Clarke et al.|BORIS (University Library Bern)|2022Cited by 311
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocolMatthew R. Sydes, Nicholas D. James, Melissa Spears et al.|Annals of Oncology|2018Cited by 252
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocolGerhardt Attard, Robin Millman, Laura Murphy et al.|The Lancet Oncology|2023Cited by 110